The Board of Directors of Kvika banki hf. is set to approve the financial statements of the Group for the second quarter and first six months of 2026 at a board meeting on Wednesday 12 August. The financial statements will subsequently be published after the domestic market has closed. A presentation for shareholders and market participants will be held at 08:30 on Thursday, 13 August, at the Bank’s headquarters at Katrínartún 2, Reykjavík. At the meeting, Ármann Þorvaldsson, CEO, and Eiríkur Magnús Jensson, CFO, will present the Group’s financial results. The presentation will be conducted in Icelandic and will be streamed live. Further, a recording of the meeting with English subtitles will later be made available on Kvika’s website. Meeting participants will be able to send questions before or during the meeting via ir@kvika.is The...

Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol “ALPS” in October 2025, Marking the Company’s Transition to the U.S. Public Markets KUALA LUMPUR, Malaysia, Aug. 07, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update. The Company has filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (the “SEC”) on August...

TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2026 and provided a corporate update. The second quarter of 2026 marked a significant milestone in the Company’s evolution as Spectral completed its U.S. Food and Drug Administration (“FDA”) Premarket Approval (“PMA”) application for PMX, reported positive 12-month follow-up results from the Tigris trial, and advanced into the FDA’s substantive review process following acceptance of the PMA application. During the quarter, the Company also continued to preparations for potential commercialization alongside its exclusive U.S....

HOUSTON, Aug. 07, 2026 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported second-quarter 2026 results and provided the following highlights: Second-Quarter 2026 ResultsSecond-quarter Net income attributable to PAA of $1.830 billion, including a net gain of approximately $1.6 billion from the Canadian NGL Business divestiture, and Net cash provided by operating activities of $956 million Delivered strong second-quarter Adjusted EBITDA attributable to PAA of $738 million Pro forma leverage ratio at quarter-end was 3.3x reflecting approximately $2.9 billion of debt reduction funded with proceeds from the Canadian NGL Business divestiture and toward the low-end of our target range of 3.25 to 3.75x Paid a quarterly cash distribution of $0.4175 per unit ($1.67 per...

Half-year financial report 2026Regulated information 1 August 2026 The board of directors of Financière de Tubize has established the 2026 half-year report. This report is available on the website www.financiere-tubize.be.Profit for the first half of 2026: € 100.8 million (€ 95.6 million in 2025, + 5.4%), Dividend received from UCB: € 102.3 million (€ 1.45 per share, an increase of 4.3% compared to the previous year), 2025 Dividend paid to Financière de Tubize’s shareholders in 2026 of € 48.1 million (€ 1.08 per share, an increase of 3.8% compared to the previous year), Acquisition, in 2026, of 15,783 UCB shares, for a total amount of € 4.05 million, at an average price of € 256.4. Our stake in UCB has increased from 36.28% on 31 December 2025 to 36,29% on 30 June 2026.

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026. Recent HighlightsGenerated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025.  Reported second quarter 2026 net loss of $(15.9) million and adjusted EBITDA of $(3.5) million in the second quarter 2026. Reduced year-to-date cash usage by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. Initiated limited market release of SuperBite™ Compression...

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 – $1,140 million and adjusted non-GAAP EBITDA of $285 – $300 millionPRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026. “In the second quarter, we delivered outstanding...

FREMONT, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today reported financial results for its second quarter ended June 30, 2026. “We delivered a strong second quarter, with revenue and shipments both increasing 36% year over year,” said Dr. David Wang, President and Chief Executive Officer of ACM. “Revenue growth was led by the ECP and advanced packaging categories, which grew 168% and 153%, respectively, reflecting the growing contribution of our broader product portfolio. During the quarter, we shipped our 2,000th ECP chamber, an important milestone that demonstrates the increasing adoption of our ECP technology in high-volume manufacturing of logic, memory and 3D packaging....

EUROCASTLE INVESTMENT LIMITED                                        FOR IMMEDIATE RELEASEContact:        Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481 723450         Eurocastle Releases Second Quarter and First Half 2026 Financial Results Guernsey, 7 August 2026 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today has released its financial report for the six months ended 30 June 2026. Q2 NAV increase of 4% to €22.0 million, or €21.81 per share: Driven by the sale of an underlying real estate investment in EPIF at a significant premium, resulting in a 26% quarter-on-quarter increase in the value of Eurocastle’s interest in EPIF.                             Q1 2026 NAV   Q2 Cash Movement   Q2 FV Movement   Q2 2026 NAV    €’m € p.s.   €’m €...

Suominen Corporation’s Half-Year Financial Report on August 7, 2026, at 9:00 a.m. (EEST) Suominen Corporation’s Half-Year Financial Report for January 1–June 30, 2026: Improved net sales and comparable EBITDA in the second quarter  In this financial report, the figures shown in brackets refer to the comparison period last year if not otherwise stated. April–June 2026 in brief:Net sales increased by 5.8% and amounted to EUR 105.6 million (99.8). Comparable EBITDA was EUR 4.3 million (3.2) Cash flow from operations was EUR -4.5 million (-10.1) Gearing 51.6% (85.5%) following successful rights issueJanuary–June 2026 in brief:Net sales decreased 7.4% and amounted to EUR 201.2 million (217.3) Comparable EBITDA was EUR 6.5 million (7.3) Cash flow from operations was EUR 0.0 million (-10.5)Outlook for 2026 Suominen expects that its comparable...